It’s time to flip the script on IBS-D.

Find out if you may qualify for the PREVAIL study.

The PREVAIL study is enrolling now

The PREVAIL clinical research study is evaluating an investigational medication in people with irritable bowel syndrome with diarrhea (IBS-D). The study doctors want to learn more about how this medication may help control IBS-D. “Investigational” means that the medication is still being tested and isn’t approved for use by the general public.

What can I expect if I take part?

If you take part in the PREVAIL study, you’ll be assigned to 1 of 3 study groups. Two of these groups will receive the investigational medication, while the third will receive placebo. Placebo looks like the investigational medication, but it contains no active drug.

Investigational drug dose 1

Investigational drug dose 2

Placebo
 

If you take part in the PREVAIL study, you’ll be assigned to 1 of 3 study groups. Two of these groups will receive the investigational medication, while the third will receive placebo. Placebo looks like the investigational medication, but it contains no active drug.

You will receive study drug (the investigational medication or placebo) for the length of the study.

The study drug will be a tablet that you’ll take by mouth. Your study doctor will tell you how often to take it.

Study tests include physical examinations, ECGs (electrocardiograms), and blood and urine samples.

You will participate for up to 19 weeks and have 8 visits at the study clinic.

You may receive reimbursement for your time and travel.

You may leave the study at any time.

But the first step is finding out if you may qualify. Please take the study questionnaire to see if the PREVAIL study may be an option for you.

Get started.